翻译后修饰介导的膜表面稳态调控与胶质母细胞瘤免疫可见性重塑

Post-translational modification-mediated regulation of membrane surface homeostasis and immune visibility remodeling in glioblastoma

摘要

胶质母细胞瘤（glioblastoma，GBM）对免疫治疗总体反应有限，传统基于程序性死亡配体1（programmed death ligand 1，PD-L1）、主要组织相容性复合体Ⅰ类分子（major histocompatibility complex class Ⅰ，MHC-Ⅰ）、分化簇47（cluster of differentiation 47，CD47）等免疫相关分子表达水平的解释，尚难以充分揭示其免疫逃逸和治疗抵抗机制。研究表明，GBM免疫逃逸不仅取决于这些分子的表达丰度，还与其翻译后修饰介导的膜表面稳态调控密切相关，包括蛋白成熟、质膜递送、膜表面驻留、内吞回收、降解分流及细胞外囊泡输出等动态过程。在这一框架下，“免疫可见性”可被理解为肿瘤细胞及其释放的细胞外囊泡在特定时空背景下可被免疫系统识别、接触、杀伤或吞噬的功能性表面状态。论文重点阐述PD-L1、MHC-Ⅰ、CD47及细胞外囊泡在GBM中调控适应性免疫逃逸、先天免疫逃逸和分布式免疫抑制的机制，并评估其作为动态生物标志物和联合治疗靶点的转化潜力。该理论框架提示，GBM精准免疫治疗研究应由静态表达检测转向对膜表面可用性、翻译后修饰状态及囊泡输出特征的综合评估，并进一步关注蛋白成熟、转运、稳定性维持及囊泡释放等上游调控节点的导向干预策略。

Abstract

Glioblastoma（GBM）exhibits limited response to immunotherapy，and conventional explanations based on the expression levels of immune-related molecules such as programmed death ligand 1（PD-L1），major histocompatibility complex class Ⅰ（MHC-Ⅰ），and cluster of differentiation 47（CD47）have proven insufficient to fully elucidate its immune evasion and therapy resistance mechanisms. Evidence indicates that GBM immune escape depends not only on the abundance of these molecules but also on their post-translational modification（PTM）-mediated regulation of membrane surface homeostasis，including protein maturation，plasma membrane delivery，surface retention，endocytic recycling，degradation，and extracellular vesicle（EV）export. Within this framework，“immune visibility”can be defined as the functional surface state in which tumor cells and their released EVs are recognizable，accessible，and susceptible to immune detection，engagement，killing，or phagocytosis in specific spatial and temporal contexts. This review emphasizes the regulatory roles of PD-L1，MHC-Ⅰ，CD47，and EVs in adaptive immune evasion，innate immune escape，and distributed immunosuppression in GBM，and evaluates their translational potential as dynamic biomarkers and targets for combination therapy. The proposed framework suggests that precision immunotherapy research in GBM should shift from static expression assessment to integrated evaluation of membrane surface availability，PTM status，and EV-mediated output，while further addressing upstream regulatory nodes that govern protein maturation，trafficking，stability，and vesicle release for mechanism-based therapeutic interventions.

关键词

胶质母细胞瘤 / 免疫可见性 / 翻译后修饰 / 膜表面稳态调控 / 免疫逃逸 / 细胞外囊泡

Key words

glioblastoma / immune visibility / post-translational modification / membrane surface homeostasis regulation / immune evasion / extracellular vesicle

参考文献

[1] MILLER K D, OSTROM Q T, KRUCHKO C, et al. Brain and other central nervous system tumor statistics，2021[J]. CA Cancer J Clin, 2021, 71(5):381-406

[2] TAN A C, ASHLEY D M, LÓPEZ G Y, et al. Management of glioblastoma：state of the art and future directions[J]. CA Cancer J Clin, 2020, 70(4):299-312

[3] WEN P Y, WELLER M, LEE E Q, et al. Glioblastoma in adults：a Society for Neuro—Oncology（SNO）and European Society of Neuro—Oncology（EANO）consensus review on current management and future directions[J]. Neuro Oncol, 2025, 27(11):2751-2788

[4] NASSIRI F, PATIL V, YEFET L S, et al. Oncolytic DNX—2401 virotherapy plus pembrolizumab in recurrent glioblastoma：a phase 1/2 trial[J]. Nat Med, 2023, 29(6):1370-1378

[5] DUERINCK J, LESCRAUWAET L, DIRVEN I, et al. Intracranial administration of anti—PD—1 and anti—CTLA—4 immune checkpoint—blocking monoclonal antibodies in patients with recurrent high—grade glioma[J]. Neuro—Oncology, 2024, 26(12):2208-2221

[6] AHLUWALIA M S, REARDON D A, ABAD A P, et al. Phase IIa study of SurVaxM plus adjuvant temozolomide for newly diagnosed glioblastoma[J]. J Clin Oncol, 2023, 41(7):1453-1465

[7] BAGLEY S J, BINDER Z A, LAMRANI L, et al. Repeated peripheral infusions of anti—EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma：a phase 1 trial[J]. Nat Cancer, 2024, 5(3):517-531

[8] MCFALINE—FIGUEROA J R, SUN L, YOUSSEF G C, et al. Neoadjuvant anti—PD1 immunotherapy for surgically accessible recurrent glioblastoma：clinical and molecular outcomes of a stage 2 single—arm expansion cohort[J]. Nat Commun, 2024, 15:10757

[9] LIAU L M, ASHKAN K, BREM S, et al. Association of autologous tumor lysate—loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma：a phase 3 prospective externally controlled cohort trial[J]. JAMA Oncol, 2023, 9(1):112-121

[10] OMURO A, BRANDES A A, CARPENTIER A F, et al. Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter：an international randomized phase Ⅲ trial[J]. Neuro Oncol, 2023, 25(1):123-134

[11] BROWN C E, HIBBARD J C, ALIZADEH D, et al. Locoregional delivery of IL—13Rα2—targeting CAR—T cells in recurrent high—grade glioma：a phase 1 trial[J]. Nat Med, 2024, 30(4):1001-1012

[12] LI X Y, ZHAO L F, LI W Z, et al. HER2—targeting CAR—T cells show highly efficient anti—tumor activity against glioblastoma both in vitro and in vivo [J]. Genes Immun, 2024, 25(3):201-208

[13] DECORDOVA S, SHASTRI A, TSOLAKI A G, et al. Molecular heterogeneity and immunosuppressive microenvironment in glioblastoma[J]. Front Immunol, 2020, 11:1402

[14] WANG X D, GE Y Z, HOU Y T, et al. Single—cell atlas reveals the immunosuppressive microenvironment and Treg cells landscapes in recurrent glioblastoma[J]. Cancer Gene Ther, 2024, 31(5):790-801

[15] CHEN A X, GARTRELL R D, ZHAO J F, et al. Single—cell characterization of macrophages in glioblastoma reveals MARCO as a mesenchymal pro—tumor marker[J]. Genome Med, 2021, 13(1):88

[16] YEO A T, RAWAL S, DELCUZE B, et al. Single—cell RNA sequencing reveals evolution of immune landscape during glioblastoma progression[J]. Nat Immunol, 2022, 23(6):971-984

[17] CHAN L C, LI C W, XIA W Y, et al. IL—6/JAK1 pathway drives PD—L1 Y112 phosphorylation to promote cancer immune evasion[J]. J Clin Invest, 2019, 129(8):3324-3338

[18] LI C W, LIM S O, XIA W Y, et al. Glycosylation and stabilization of programmed death ligand—1 suppresses T—cell activity[J]. Nat Commun, 2016, 7:12632

[19] GAO Y, NIHIRA N T, BU X, et al. Acetylation—dependent regulation of PD—L1 nuclear translocation dictates the efficacy of anti—PD—1 immunotherapy[J]. Nat Cell Biol, 2020, 22(9):1064-1075

[20] XU F F, SUN H M, FANG R P, et al. The modulation of PD—L1 induced by the oncogenic HBXIP for breast cancer growth[J]. Acta Pharmacol Sin, 2022, 43(2):429-445

[21] ROMEO M A, GILARDINI MONTANI M S, SANTARELLI R, et al. Acetylation increases expression，interaction with TRAPPC4 and surface localization of PD—L1[J]. Discov Oncol, 2023, 14(1):152

[22] ZHU D, XU R D, HUANG X P, et al. Deubiquitinating enzyme OTUB1 promotes cancer cell immunosuppression via preventing ER—associated degradation of immune checkpoint protein PD—L1[J]. Cell Death Differ, 2021, 28(6):1773-1789

[23] CHEN Y J, LI Y S, WU L. Protein S—palmitoylation modification：implications in tumor and tumor immune microenvironment[J]. Front Immunol, 2024, 15:1337478

[24] SHAHID M, KIM M, JIN P, et al. S—palmitoylation as a functional regulator of proteins associated with cisplatin resistance in bladder cancer[J]. Int J Biol Sci, 2020, 16(14):2490-2505

[25] GHAZI B, HARMAK Z, RGHIOUI M, et al. Decoding the secret of extracellular vesicles in the immune tumor microenvironment of the glioblastoma：on the border of kingdoms[J]. Front Immunol, 2024, 15:1423232

[26] HIMES B T, PETERSON T E, DE MOOIJ T, et al. The role of extracellular vesicles and PD—L1 in glioblastoma—mediated immunosuppressive monocyte induction[J]. Neuro Oncol, 2020, 22(7):967-978

[27] ZHANG J F, BU X, WANG H Z, et al. Cyclin D—CDK4 kinase destabilizes PD—L1 via cullin 3—SPOP to control cancer immune surveillance[J]. Nature, 2018, 553(7686):91-95

[28] YU X F, LI W, LIU H D, et al. PD—L1 translocation to the plasma membrane enables tumor immune evasion through MIB2 ubiquitination[J]. J Clin Invest, 2023, 133(3):e160456

[29] CHOI S H, MANI M, KIM J, et al. DRG2 is required for surface localization of PD—L1 and the efficacy of anti—PD—1 therapy[J]. Cell Death Discov, 2024, 10(1):260

[30] REN Y M, QIAN Y, AI L Y, et al. TRAPPC4 regulates the intracellular trafficking of PD—L1 and antitumor immunity[J]. Nat Commun, 2021, 12(1):5405

[31] WANG H B, YAO H, LI C S, et al. HIP1R targets PD—L1 to lysosomal degradation to alter T cell—mediated cytotoxicity[J]. Nat Chem Biol, 2019, 15(1):42-50

[32] LONG Y R, CHEN R Q, YU X L, et al. Suppression of tumor or host intrinsic CMTM6 drives antitumor cytotoxicity in a PD—L1—independent manner[J]. Cancer Immunol Res, 2023, 11(2):241-260

[33] MIAO B P, HU Z Q, MEZZADRA R, et al. CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD—L1[J]. Cancer Cell, 2023, 41(10):1817-1828

[34] DU L Y, LEE J H, JIANG H F, et al. β—Catenin induces transcriptional expression of PD—L1 to promote glioblastoma immune evasion[J]. J Exp Med, 2020, 217(11):e20191115

[35] GUO M X, YUAN Z, JIN X, et al. Inhibition of ICAM1 diminishes stemness and enhances antitumor immunity in glioblastoma via β—catenin/PD—L1 signaling[J]. Nat Commun, 2025, 16(1):8642

[36] JUNG M Y, AIBAIDULA A, BROWN D A, et al. Superinduction of immunosuppressive glioblastoma extracellular vesicles by IFN—γ through PD—L1 and IDO1[J]. Neurooncol Adv, 2022, 4(1):vdac017

[37] SCHWEIGER M W, AMOOZGAR Z, REPITON P, et al. Glioblastoma extracellular vesicles modulate immune PD—L1 expression in accessory macrophages upon radiotherapy[J]. iScience, 2024, 27(2):108807

[38] VESELY M D, ZHANG T X, CHEN L P. Resistance mechanisms to anti—PD cancer immunotherapy[J]. Annu Rev Immunol, 2022, 40:45-74

[39] MAGGS L, SADAGOPAN A, MOGHADDAM A S, et al. HLA class I antigen processing machinery defects in antitumor immunity and immunotherapy[J]. Trends Cancer, 2021, 7(12):1089-1101

[40] CHEN X F, LU Q, ZHOU H, et al. A membrane—associated MHC—I inhibitory axis for cancer immune evasion[J]. Cell, 2023, 186(18):3903-3920

[41] MENG C Y, ZHANG H P, YI X W, et al. Reversal of tumour immune evasion via enhanced MHC—Class—I antigen presentation by a dual—functional RNA regulated system[J]. Mol Cancer, 2025, 24(1):258

[42] DEMEL U M, BÖGER M, YOUSEFIAN S, et al. Activated SUMOylation restricts MHC class I antigen presentation to confer immune evasion in cancer[J]. J Clin Investig, 2022, 132(9):e152383

[43] LAUSS M, PHUNG B, BORCH T H, et al. Molecular patterns of resistance to immune checkpoint blockade in melanoma[J]. Nat Commun, 2024, 15:3075

[44] LIN W Z, CHEN L, ZHANG H J, et al. Tumor—intrinsic YTHDF1 drives immune evasion and resistance to immune checkpoint inhibitors via promoting MHC—I degradation[J]. Nat Commun, 2023, 14(1):265

[45] WU X Y, LI T H, JIANG R, et al. Targeting MHC—I molecules for cancer：function，mechanism，and therapeutic prospects[J]. Mol Cancer, 2023, 22(1):194

[46] JONGSMA M L M, DE WAARD A A, RAABEN M, et al. The SPPL3—defined glycosphingolipid repertoire orchestrates HLA class I—mediated immune responses[J]. Immunity, 2021, 54(1):132-150

[47] BUTT N S, KURDI M, FADUL M M, et al. Major histocompatibility class—I（MHC—I）downregulation in glioblastoma is a poor prognostic factor but not a predictive indicator for treatment failure[J]. Pathol Res Pract, 2023, 250:154816

[48] SINGH K, FOSTER M W, VIOLETTE M J, et al. A surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC—I expression and CD8⁺ infiltration in glioma[J]. Sci Rep, 2025, 15:37112

[49] LI D Q, ZHANG Q, LI L, et al. β2—microglobulin maintains glioblastoma stem cells and induces M2—like polarization of tumor—associated macrophages[J]. Cancer Res, 2022, 82(18):3321-3334

[50] BURSTER T, GÄRTNER F, BULACH C, et al. Regulation of MHC I molecules in glioblastoma cells and the sensitizing of NK cells[J]. Pharmaceuticals, 2021, 14(3):236

[51] LERNER E C, WORONIECKA K I, D'ANNIBALLE V M, et al. CD8⁺ T cells maintain killing of MHC—I—negative tumor cells through the NKG2D—NKG2DL axis[J]. Nat Cancer, 2023, 4(9):1258-1272

[52] LIU Y E, WANG Y J, YANG Y R, et al. Emerging phagocytosis checkpoints in cancer immunotherapy[J]. Sig Transduct Target Ther, 2023, 8:104

[53] HU J Y, DONG F, HE Y, et al. LRIG2 promotes glioblastoma progression by modulating innate antitumor immunity through macrophage infiltration and polarization[J]. J Immunother Cancer, 2022, 10(9):e004452

[54] DU L Y, SU Z P, WANG S L, et al. EGFR—induced and c—src—mediated CD47 phosphorylation inhibits TRIM21—dependent polyubiquitylation and degradation of CD47 to promote tumor immune evasion[J]. Adv Sci（Weinh）, 2023, 10(27):e2206380

[55] JIANG N, XIE B W, XIAO W W, et al. Fatty acid oxidation fuels glioblastoma radioresistance with CD47—mediated immune evasion[J]. Nat Commun, 2022, 13(1):1511

[56] QI Y H, ZHAO R R, ZHANG X L, et al. Targeting hypoxic exosomal IGFBP2 overcomes CD47—mediated immune evasion in glioblastoma[J]. Cell Death Dis, 2026, 17(1):192

[57] LI F, LV B K, LIU Y, et al. Blocking the CD47—SIRPα axis by delivery of anti—CD47 antibody induces antitumor effects in glioma and glioma stem cells[J]. Oncoimmunology, 2018, 7(2):e1391973

[58] LI Y Y, CAO Y F, HE L Y, et al. Cisplatin reduces immunosuppression caused by tumor—associated macrophages through downregulating CD47—SIRPα signaling in glioblastoma[J]. Biochim Biophys Acta Mol Basis Dis, 2025, 1871(6):167876

[59] ROUATBI N, WALTERS A A, ZAM A, et al. CD47 knockout using CRISPR—Cas9 RNA lipid nanocarriers results in reduced mesenchymal glioblastoma growth in vivo [J]. Adv Sci（Weinh）, 2025, 12(12):e2407262

[60] SALLMAN D A, AL MALKI M M, ASCH A S, et al. Magrolimab in combination with azacitidine in patients with higher—risk myelodysplastic syndromes：final results of a phase lb study[J]. J Clin Oncol, 2023, 41(15):2815-2826

[61] SHEYBANI N D, BREZA V R, PAUL S, et al. ImmunoPET—informed sequence for focused ultrasound—targeted mCD47 blockade controls glioma[J]. J Control Release, 2021, 331:19-29

[62] GRANER M W. Roles of extracellular vesicles in high—grade gliomas：tiny particles with outsized influence[J]. Annu Rev Genomics Hum Genet, 2019, 20:331-357

[63] LYUKMANOVA E N, KIRICHENKO A V, MEDYANIK I A, et al. Extracellular vesicles from plasma of patients with glioblastoma promote invasion of glioblastoma cells even after tumor resection[J]. Biomedicines, 2024, 12(12):2834

[64] TANKOV S, PETROVIC M, LECOULTRE M, et al. Hypoxic glioblastoma—cell—derived extracellular vesicles impair cGAS—STING activity in macrophages[J]. Cell Commun Signal, 2024, 22(1):144

[65] AIBAIDULA A Z, FAIN C E, GARCIA L C, et al. Spectral flow cytometry identifies distinct nonneoplastic plasma extracellular vesicle phenotype in glioblastoma patients[J]. Neurooncol Adv, 2023, 5(1):vdad082

[66] CAPONNETTO F, DALLA E, MANGONI D, et al. The miRNA content of exosomes released from the glioma microenvironment can affect malignant progression[J]. Biomedicines, 2020, 8(12):564

[67] RICKLEFS F L, WOLLMANN K, SALVIANO—SILVA A, et al. Circulating extracellular vesicles as biomarker for diagnosis，prognosis，and monitoring in glioblastoma patients[J]. Neuro Oncol, 2024, 26(7):1280-1291

[68] LARIOS J, MERCIER V, ROUX A, et al. ALIX—and ESCRT—Ⅲ—dependent sorting of tetraspanins to exosomes[J]. J Cell Biol, 2020, 219(3):e201904113

[69] BERTIN A, DE FRANCESCHI N, DE LA MORA E, et al. Human ESCRT—Ⅲ polymers assemble on positively curved membranes and induce helical membrane tube formation[J]. Nat Commun, 2020, 11:2663

[70] CHOEZOM D, GROSS J C. Neutral sphingomyelinase 2 controls exosome secretion by counteracting V—ATPase—mediated endosome acidification[J]. J Cell Sci, 2022, 135(5):jcs259324

[71] OSTROWSKI M, CARMO N B, KRUMEICH S, et al. Rab27a and Rab27b control different steps of the exosome secretion pathway[J]. Nat Cell Biol, 2010, 12(1):19-30

[72] XU F, LUO S M, LU P P, et al. Composition，functions，and applications of exosomal membrane proteins[J]. Front Immunol, 2024, 15:1408415

[73] LEE H, LI C H, ZHANG Y, et al. Caveolin—1 selectively regulates microRNA sorting into microvesicles after noxious stimuli[J]. J Exp Med, 2019, 216(9):2202-2220

[74] REDZIC J S, KENDRICK A A, BAHMED K, et al. Extracellular vesicles secreted from cancer cell lines stimulate secretion of MMP—9，IL—6，TGF—β1 and EMMPRIN[J]. PLoS One, 2013, 8(8):e71225

[75] MENCK K, SCHARF C, BLECKMANN A, et al. Tumor—derived microvesicles mediate human breast cancer invasion through differentially glycosylated EMMPRIN[J]. J Mol Cell Biol, 2015, 7(2):143-153

[76] WILLIAMS C, PAZOS R, ROYO F, et al. Assessing the role of surface glycans of extracellular vesicles on cellular uptake[J]. Sci Rep, 2019, 9:11920

[77] NISHIDA—AOKI N, TOMINAGA N, KOSAKA N, et al. Altered biodistribution of deglycosylated extracellular vesicles through enhanced cellular uptake[J]. J Extracell Vesicles, 2020, 9(1):1713527

[78] CLOS—SANSALVADOR M, GARCIA S G, MORÓN—FONT M, et al. N—glycans in immortalized mesenchymal stromal cell—derived extracellular vesicles are critical for EV—cell interaction and functional activation of endothelial cells[J]. Int J Mol Sci, 2022, 23(17):9539

[79] HALLAL S, TUZESI Á, GRAU G E, et al. Understanding the extracellular vesicle surface for clinical molecular biology[J]. J Extracellular Vesicle, 2022, 11(10):e12260

[80] KUNADT M, ECKERMANN K, STUENDL A, et al. Extracellular vesicle sorting of α—synuclein is regulated by sumoylation[J]. Acta Neuropathol, 2015, 129(5):695-713

[81] CHEN C H, ZHENG H H, LUO Y M, et al. SUMOylation promotes extracellular vesicle—mediated transmission of lncRNA ELNAT1 and lymph node metastasis in bladder cancer[J]. J Clin Invest, 2021, 131(8):e146431

[82] LIU Y, ZHOU F, ALI H B, et al. Immunotherapy for glioblastoma：current state，challenges，and future perspectives[J]. Cell Mol Immunol, 2024, 21(12):1354-1375

[83] MORENO—SANCHEZ P M, REZAEIPOUR M, INDERBERG E M, et al. Immunosuppressive mechanisms and therapeutic interventions shaping glioblastoma immunity[J]. Nat Cancer, 2026, 7(1):29-42

[84] WEATHERS S P, LI X Q, ZHU H F, et al. Improved overall survival in an anti—PD—L1 treated cohort of newly diagnosed glioblastoma patients is associated with distinct immune，mutation，and gut microbiome features：a single arm prospective phase Ⅰ/Ⅱ trial[J]. Nat Commun, 2025, 16:3950

[85] YU K K H, BASU S, BAQUER G, et al. Investigative needle core biopsies support multimodal deep—data generation in glioblastoma[J]. Nat Commun, 2025, 16(1):3957

[86] AJAIB S, WINTER—LUKE J, DIGBY R J, et al. Spatial profiling of longitudinal glioblastoma reveals consistent changes in cellular architecture，post—treatment[J]. Neuro Oncol, 2025, 27(12):3145-3160

[87] LANDRY A P, ELLENBOGEN Y, AJISEBUTU A, et al. Biomarkers of immunotherapy response in neuro—oncology[J]. Neuro Oncol Adv, 2025, 7(Suppl 4):32-40

[88] VAN OPIJNEN M P, DE VOS F Y F, CUPPEN E, et al. The role of molecular biomarkers in recurrent glioblastoma trials：an assessment of the current trial landscape of genome—driven oncology[J]. Med Oncol, 2024, 41(11):250

[89] MENACEUR VANDENBROUCKE C， UNNIKRISHNAN K, ITA M I, et al. Extracellular vesicles as liquid biopsy tools for personalized therapeutic goals in glioblastoma[J]. Brain, 2026, 149(5):1452-1468

[90] LYUKMANOVA E N, KIRICHENKO A V, MEDYANIK I A, et al. Extracellular vesicles from plasma of patients with glioblastoma promote invasion of glioblastoma cells even after tumor resection[J]. Biomedicines, 2024, 12(12):2834

[91] ZHANG Z, LOBB R J, TOONEY P, et al. Monitoring glioblastoma extracellular vesicle evolution using a nanodiagnostic platform to detect glioma stem cells driving recurrent disease[J]. Sci Adv, 2026, 12(5):eadt2804

[92] ZHANG X, LI J J, HUANG Y Y, et al. Plasma extracellular vesicles from recurrent GBMs carrying LDHA to activate glioblastoma stemness by enhancing glycolysis[J]. Theranostics, 2025, 15(8):3655-3672

[93] KANSHA T, MA X J, WANG H, et al. Exosomal PD—L1 detection in cancer predictive biomarker for response to immune checkpoint blockade therapy[J]. Front Immunol, 2025, 16:1603855

[94] AIBAIDULA A, GHARIBI LORON A, BOUCHAL S M, et al. Plasma extracellular vesicles as liquid biopsies for glioblastoma：biomarkers，subpopulation enrichment，and clinical translation[J]. Int J Mol Sci, 2025, 26(23):11686

[95] HALLAL S M, TuZESI Á, SIDA L A, et al. Glioblastoma biomarkers in urinary extracellular vesicles reveal the potential for a‘liquid gold'biopsy[J]. Br J Cancer, 2024, 130(5):836-851

基金资助

国家自然科学基金(82573129)